BioCentury | Mar 13, 2021
Finance

March 12 Quick Takes: Longboard, Prometheus rise after pricing IPOs; plus Monte Rosa, Nano Cures and CalciMedica

...round led by Quark Venture and Global Health Sciences Fund, with backing from existing investors Valence Life Sciences...
BioCentury | Jun 6, 2016
Finance

Buy low, Celator

...raised $43.7 million through the sale of stock at $9.50 (see BioCentury, May 30) . Valence Life Sciences...
BioCentury | Sep 2, 2013
Finance

Amgen's preemptive strike

...three or more prior therapies. The primary endpoint is overall survival (OS). Eric Roberts of Valence Life Sciences...
BioCentury | Aug 12, 2013
Finance

A disciplined crowd

...had been a tough decade or so for biotech companies wanting to go public," said Valence Life Sciences'...
BioCentury | May 6, 2013
Financial News

Celator completes private placement of common stock and warrants

...$3.12 Shares after offering: 26 million Placement agents: Roth Capital Partners; National Securities Corp. Investors: Valence Life Sciences...
BioCentury | May 6, 2013
Company News

Celator board of directors update

...Celator Pharmaceuticals Inc. , Princeton, N.J. Business: Cancer Appointed: Scott Morenstein, managing director at Valence Life Sciences WIR Staff...
BioCentury | May 7, 2012
Finance

Venture tracks

...Venture tracks Scott Morenstein was promoted to managing director at Valence Life Sciences . He was principal at...
BioCentury | Feb 27, 2012
Financial News

Caxton Advantage Venture Partners financial update

...The life sciences team of Caxton Advantage will form Valence Life Sciences, an independent investment firm focused on...
BioCentury | Feb 27, 2012
Finance

Caxton team to Valence

...Valence The founders of Caxton Advantage Venture Partners are leaving to start a new firm, Valence Life Sciences...
BioCentury | Feb 24, 2012
Financial News

Caxton Advantage launches independent firm

...Life science investment firm Caxton Advantage Venture Partners announced the formation of Valence Life Sciences, an independent investment...
Items per page:
1 - 10 of 10
BioCentury | Mar 13, 2021
Finance

March 12 Quick Takes: Longboard, Prometheus rise after pricing IPOs; plus Monte Rosa, Nano Cures and CalciMedica

...round led by Quark Venture and Global Health Sciences Fund, with backing from existing investors Valence Life Sciences...
BioCentury | Jun 6, 2016
Finance

Buy low, Celator

...raised $43.7 million through the sale of stock at $9.50 (see BioCentury, May 30) . Valence Life Sciences...
BioCentury | Sep 2, 2013
Finance

Amgen's preemptive strike

...three or more prior therapies. The primary endpoint is overall survival (OS). Eric Roberts of Valence Life Sciences...
BioCentury | Aug 12, 2013
Finance

A disciplined crowd

...had been a tough decade or so for biotech companies wanting to go public," said Valence Life Sciences'...
BioCentury | May 6, 2013
Financial News

Celator completes private placement of common stock and warrants

...$3.12 Shares after offering: 26 million Placement agents: Roth Capital Partners; National Securities Corp. Investors: Valence Life Sciences...
BioCentury | May 6, 2013
Company News

Celator board of directors update

...Celator Pharmaceuticals Inc. , Princeton, N.J. Business: Cancer Appointed: Scott Morenstein, managing director at Valence Life Sciences WIR Staff...
BioCentury | May 7, 2012
Finance

Venture tracks

...Venture tracks Scott Morenstein was promoted to managing director at Valence Life Sciences . He was principal at...
BioCentury | Feb 27, 2012
Financial News

Caxton Advantage Venture Partners financial update

...The life sciences team of Caxton Advantage will form Valence Life Sciences, an independent investment firm focused on...
BioCentury | Feb 27, 2012
Finance

Caxton team to Valence

...Valence The founders of Caxton Advantage Venture Partners are leaving to start a new firm, Valence Life Sciences...
BioCentury | Feb 24, 2012
Financial News

Caxton Advantage launches independent firm

...Life science investment firm Caxton Advantage Venture Partners announced the formation of Valence Life Sciences, an independent investment...
Items per page:
1 - 10 of 10